908864-98-2

Basic information

• Product Name: 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine
• Synonyms: 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine;5-bromo-N,N-dimethyl-3-Pyridinemethan amine;3-Bromo-5-(N,N-dimethylaminomethyl)pyridine
• CAS NO: 908864-98-2
• Molecular Formula: C8H11BrN2
• Molecular Weight: 215.1
• Mol File: 908864-98-2.mol
• Article Data: 38

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine(908864-98-2)
• EPA Substance Registry System: 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine(908864-98-2)

Safety Data

• Hazardous Substances Data: 908864-98-2(Hazardous Substances Data)

Usage

General Description

1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine is a chemical compound that consists of a pyridine ring with a bromine substituent at the 5th position and a dimethylmethanamine group attached to the 1st position. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine is known for its diverse range of biological activities and is often studied for its potential therapeutic applications. Additionally, its unique chemical structure makes it a valuable building block in organic synthesis and drug discovery.

Upstream product

• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 124-40-3 dimethyl amine 
• 183608-47-1 N-methyl-N-methoxy-5-bromopyridine-3-carboxamide 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 506-59-2 N,N-dimethylammonium chloride 
• 39741-46-3 3-bromo-5-(chloromethyl)-pyridine hydrochloride 
• 625-92-3 3,5-dibromopyridine 

Downstream Products

• 1428065-56-8 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine 
• 919347-18-5 dimethyl{[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methyl}amine 
• 135124-70-8 (5-bromo-3-pyridinyl)methylamine 
• 219660-71-6 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 

Relevant articles and documents

SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE

The present application relates to two crystalline polymorphic forms, crystalline methanol, ethanol and tetrahydrofuran solvates and a crystalline hydrate of the compound l-(5-(3-(7-(3-fluorophenyl)-3H- imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3- yl)-N,N-dimethylmethanamine (Ipivivint), to a pharmaceutical composition comprising them and their medical use for the treatment of disorders characterized by the activation of of the Wnt signaling pathway selected from cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis and idiopathic pulmonary fibrosis. Also claimed is a process for the preparation of compounds of Formula (I) by reacting a starting material of Formula (A1) with a compound of Formula (A2).

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.